Milton Werner
Oprichter bij INHIBIKASE THERAPEUTICS, INC.
Vermogen: 2 M $ op 30-04-2024
Actieve functies van Milton Werner
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Directeur/Bestuurslid | 01-09-2008 | - |
| Algemeen Directeur | 01-09-2008 | - | |
| Oprichter | 01-09-2008 | - | |
| President | 01-09-2008 | - | |
| Investor Relations Contact | 01-09-2008 | - | |
| Winship Cancer Institute | Corporate Officer/Principal | - | - |
Loopbaan van Milton Werner
Eerdere bekende functies van Milton Werner
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Celtaxsys, Inc.
 Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | Hoofd Techniek/Wetenschap/O&O | 01-05-2007 | 01-08-2007 |
| The Rockefeller University | Corporate Officer/Principal | 01-09-1996 | 01-06-2007 |
Opleiding van Milton Werner
| University of California, Berkeley | Doctorate Degree |
| University of Southern California | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 7 |
Operationeel
| Corporate Officer/Principal | 2 |
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Sectoraal
| Consumer Services | 4 |
| Health Technology | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Celtaxsys, Inc.
Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | Health Technology |
| Winship Cancer Institute |
- Beurs
- Insiders
- Milton Werner
- Ervaring
